CombiGene AB (publ) (“CombiGene”, the “Company”) announces today that Annika Ericsson, current Director Preclinical Development, will take over the role of Chief Scientific Officer, after Karin Agerman, who has decided to leave the company.

"Karin has been a highly valued employee and part of the management team since 2018. With her solid experience and thorough understanding of drug development, combined with her sense of business, she has been very successful in driving CombiGene's development forward over the years," says CombiGene's CEO Peter Ekolind. "We will miss Karin, while at the same time we are extremely grateful for the progress she has contributed to through her knowledge and good leadership. We wish her all the best in her new role as Chief Operating Officer at Epigenica," continues Peter.

Annika has worked almost as long as Karin in the company and has solid experience in drug development of gene therapies in the preclinical phase and project management. She started by running the preclinical testing of CG01 and has subsequently been project manager in several projects, most recently for CGT2, the lipodystrophy project, and COZY02, CombiGene’s latest gene therapy project that targets severe chronic pain where there is currently a lack of good treatment options.

"Annika has many years of solid experience in gene therapy development, drug development and project management, combined with a passion for science, which makes her well suited to assume the role of Chief Scientific Officer. I am really looking forward to welcoming her to the management team and our continued collaboration in the company", concludes Peter.